Journal
JOURNAL OF HEPATOLOGY
Volume 46, Issue 6, Pages 1026-1033Publisher
ELSEVIER
DOI: 10.1016/j.jhep.2007.01.017
Keywords
renin-angiotensin system; portal hypertension; liver fibrosis; hyaluronic acid; portal pressure
Categories
Ask authors/readers for more resources
Background/Aims: The renin-angiotensin system plays an important role in hepatic fibrogenesis and in portal hypertension. To examine the long-term effects of Candesartan cilexetil, an angiotensin type 1 (AT1) receptor blocker, on portal-systemic haemodynamics and on liver fibrosis. Methods: Forty-seven compensated Child A and Child B (<= 8) cirrhotic patients were randomly assigned to receive Candesartan cilexetil, 8 mg/d (N.24) and no treatment (N.23) for 1 year. Portal-systemic haemodynamic parameters, serological levels of procollagen (PIIINP), hyaluronic acid (HA) and transforming growth factor beta 1 (TGF beta 1) were assessed at baseline and after 12 months. Results: No patients discontinued or decreased the drug. The hepatic venous pressure gradient (HVPG) decreased significantly in treated patients (-8.4% +/- 2.4) with a reduction >20% in 25% of cases vs + 5.6% +/- 2.9 in the untreated group. HA plasma levels decreased significantly in Candesartan treated patients in whom HVPG diminished and rose in untreated patients in whom HVPG increased. Conclusions: In selected cirrhotic patients, pharmacological inhibition of the AT1 receptor is well tolerated and induced a mild reduction of portal pressure. This haemodynamic effect might be related to liver fibrogenesis activity. (C) 2007 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available